{
    "clinical_study": {
        "@rank": "109430", 
        "arm_group": [
            {
                "arm_group_label": "Amyloid Negative Subjects", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F)  and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB."
            }, 
            {
                "arm_group_label": "Amyloid Positive Subjects", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F)  and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to demonstrate the conversion of florbetapir (18F) Positron Emission\n      Tomography (PET) Standard Uptake Value ratio (SUVr) to Centiloid units."
        }, 
        "brief_title": "Florbetapir Calibration to the Centiloid Scale", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cognitively Normal Subjects\n\n               -  Males or females \u2265 21 and \u2264 45 years of age\n\n               -  Mini-mental state examination (MMSE) \u2265 29\n\n          -  Clinically Diagnosed AD Subject\n\n               -  Males or females \u2265 50 years of age\n\n               -  Meet clinical criteria for dementia due to probable AD\n\n               -  MMSE \u2265 16 and \u2264 26\n\n          -  Possible AD Subject\n\n               -  Males or females \u2265 50 years of age\n\n               -  Meet clinical criteria for dementia due to possible AD\n\n               -  MMSE \u2265 16 and \u2264 26\n\n          -  MCI Subject\n\n               -  Males or females \u2265 60 years of age with cognitive impairment (not dementia)\n\n               -  MMSE >24 and <29\n\n          -  At Risk Elderly Subject\n\n               -  Cognitively normal males or females that are known ApoE4 carriers and \u2265 75 years\n                  of age\n\n               -  MMSE \u2265 27\n\n        Exclusion Criteria:\n\n          -  Have had or currently have a diagnosis of neurodegenerative disorders other than AD\n\n          -  Have a current serious or unstable illness that could interfere with completion of\n             the study\n\n          -  Subject has a known brain lesion, pathology or traumatic brain injury\n\n          -  Have received or participated in a trial with investigational medications in the past\n             30 days\n\n          -  Have had a radiopharmaceutical imaging or treatment procedure within 7 days of  study\n             imaging session\n\n          -  Females of childbearing potential who are not surgically sterile, not refraining from\n             sexual activity or not using reliable methods of contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120664", 
            "org_study_id": "18F-AV-45-A22"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Amyloid Negative Subjects", 
                    "Amyloid Positive Subjects"
                ], 
                "intervention_name": "Florbetapir (18F)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Florbetapir F 18", 
                    "Amyvid", 
                    "18F-AV-45"
                ]
            }, 
            {
                "arm_group_label": [
                    "Amyloid Negative Subjects", 
                    "Amyloid Positive Subjects"
                ], 
                "intervention_name": "11C-PiB", 
                "intervention_type": "Drug", 
                "other_name": "Pittsburgh Compound B"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3084"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB", 
        "overall_contact": {
            "email": "clinicaloperations@avidrp.com", 
            "last_name": "Avid Clinical Operations", 
            "phone": "215-298-0700"
        }, 
        "overall_official": {
            "affiliation": "Avid Radiopharmaceuticals, Inc.", 
            "last_name": "Chief Medical Officer", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Conversion of florbetapir (18F) PET SUVr to Centiloid units", 
            "measure": "Florbetapir SUVr Conversion to Centiloid Units", 
            "safety_issue": "No", 
            "time_frame": "up to 70 minutes post injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120664"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Spearman rank correlation analysis between 11C-PiB and florbetapir (18F) SUVr as converted to centiloid units.", 
                "measure": "Correlation of florbetapir (18F) centiloid and 11C-PiB centiloid", 
                "safety_issue": "No", 
                "time_frame": "up to 70 minutes post injection"
            }, 
            {
                "description": "Variance and coefficient of variation for 11C-PiB and florbetapir (18F) SUVr.", 
                "measure": "Variability of PET Images in Control Subjects.", 
                "safety_issue": "No", 
                "time_frame": "up to 70 minutes post injection"
            }
        ], 
        "source": "Avid Radiopharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Avid Radiopharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}